Teva Pharmaceuticals Europe BV, TEVA and MSD MRK today announced that the Committee for Medicinal Products for Human Use of the European Medicines Agency adopted a positive opinion for NOMAC-E2 an investigational monophasic combined oral contraceptive tablet indicated for the use by women to prevent pregnancy.
NOMAC-E2 is a birth control pill that contains 2 steroid hormones nomegestrol acetate, a highly selective, progesterone-derived progestin and 17-beta estradiol (E2), an estrogen that is similar to the one naturally present in a woman's body. The next step for marketing authorization is review by the European Commission.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.